\BOOKMARK [-1][-]{part.1}{I Notes}{}% 1
\BOOKMARK [0][-]{chapter.1}{Introduction}{part.1}% 2
\BOOKMARK [1][-]{section.1.1}{Genetics vs Genomics}{chapter.1}% 3
\BOOKMARK [2][-]{subsection.1.1.1}{Differences}{section.1.1}% 4
\BOOKMARK [1][-]{section.1.2}{Human Genomics - the Basis}{chapter.1}% 5
\BOOKMARK [2][-]{subsection.1.2.1}{Genetic Make-Up}{section.1.2}% 6
\BOOKMARK [1][-]{section.1.3}{Inherited variants' relevance}{chapter.1}% 7
\BOOKMARK [2][-]{subsection.1.3.1}{Differences in Genetic Make-Up, an example}{section.1.3}% 8
\BOOKMARK [2][-]{subsection.1.3.2}{Somatic Variants}{section.1.3}% 9
\BOOKMARK [1][-]{section.1.4}{Experimental techniques to detect variants/aberrations}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.4.1}{Cariotyping}{section.1.4}% 11
\BOOKMARK [1][-]{section.1.5}{Sequence capture for cancer genomics}{chapter.1}% 12
\BOOKMARK [2][-]{subsection.1.5.1}{Single End \(SE\) and Paired End \(PE\) reads}{section.1.5}% 13
\BOOKMARK [0][-]{chapter.2}{Coverage}{part.1}% 14
\BOOKMARK [1][-]{section.2.1}{Local Coverage and Allelic Fraction}{chapter.2}% 15
\BOOKMARK [2][-]{subsection.2.1.1}{Mapping in NGS}{section.2.1}% 16
\BOOKMARK [1][-]{section.2.2}{Tuning the intended coverage of a NGS assay}{chapter.2}% 17
\BOOKMARK [2][-]{subsection.2.2.1}{Example on the importance of coverage}{section.2.2}% 18
\BOOKMARK [2][-]{subsection.2.2.2}{Databases}{section.2.2}% 19
\BOOKMARK [1][-]{section.2.3}{Interpreting Pair Orientations}{chapter.2}% 20
\BOOKMARK [2][-]{subsection.2.3.1}{Inversion}{section.2.3}% 21
\BOOKMARK [2][-]{subsection.2.3.2}{Tandem duplication}{section.2.3}% 22
\BOOKMARK [2][-]{subsection.2.3.3}{Inverted duplication}{section.2.3}% 23
\BOOKMARK [1][-]{section.2.4}{Summary}{chapter.2}% 24
\BOOKMARK [0][-]{chapter.3}{Genetic Fingerprinting}{part.1}% 25
\BOOKMARK [1][-]{subsection.3.0.1}{Variants used for genetic testing}{chapter.3}% 26
\BOOKMARK [1][-]{section.3.1}{SNPs features}{chapter.3}% 27
\BOOKMARK [2][-]{subsection.3.1.1}{Hardy-Weinberg equilibrium and Minor Allele frequency}{section.3.1}% 28
\BOOKMARK [2][-]{subsection.3.1.2}{Minor Allele Frequency}{section.3.1}% 29
\BOOKMARK [2][-]{subsection.3.1.3}{Projects regarding SNPs}{section.3.1}% 30
\BOOKMARK [2][-]{subsection.3.1.4}{Haplotype Blocks}{section.3.1}% 31
\BOOKMARK [2][-]{subsection.3.1.5}{Other SNPs features}{section.3.1}% 32
\BOOKMARK [2][-]{subsection.3.1.6}{Number of SNPs to select}{section.3.1}% 33
\BOOKMARK [1][-]{section.3.2}{Genetic Distance}{chapter.3}% 34
\BOOKMARK [2][-]{subsection.3.2.1}{Some questions}{section.3.2}% 35
\BOOKMARK [2][-]{subsection.3.2.2}{Further considerations}{section.3.2}% 36
\BOOKMARK [1][-]{section.3.3}{Building a SNP-based genetic test}{chapter.3}% 37
\BOOKMARK [2][-]{subsection.3.3.1}{Implementation of a probabilistic test}{section.3.3}% 38
\BOOKMARK [2][-]{subsection.3.3.2}{Example 1: Cell line passages}{section.3.3}% 39
\BOOKMARK [2][-]{subsection.3.3.3}{Individual's Relatedness \(genotype-distance\)}{section.3.3}% 40
\BOOKMARK [2][-]{subsection.3.3.4}{Example 3: Cancer susceptibility test}{section.3.3}% 41
\BOOKMARK [2][-]{subsection.3.3.5}{Genetic structure of the human population}{section.3.3}% 42
\BOOKMARK [0][-]{chapter.4}{IGV \(Integrative Genomics Viewer\)}{part.1}% 43
\BOOKMARK [1][-]{section.4.1}{Main characteristics of IGV}{chapter.4}% 44
\BOOKMARK [2][-]{subsection.4.1.1}{Igvtools}{section.4.1}% 45
\BOOKMARK [2][-]{subsection.4.1.2}{Session Files}{section.4.1}% 46
\BOOKMARK [1][-]{section.4.2}{Some of the main utilizations}{chapter.4}% 47
\BOOKMARK [2][-]{subsection.4.2.1}{RNA-seq alignments}{section.4.2}% 48
\BOOKMARK [2][-]{subsection.4.2.2}{Study of variants}{section.4.2}% 49
\BOOKMARK [1][-]{section.4.3}{Exercise}{chapter.4}% 50
\BOOKMARK [2][-]{subsection.4.3.1}{Task B}{section.4.3}% 51
\BOOKMARK [0][-]{chapter.5}{Tumor Evolution Studies via NGS data}{part.1}% 52
\BOOKMARK [1][-]{section.5.1}{Tumor evolution}{chapter.5}% 53
\BOOKMARK [2][-]{subsection.5.1.1}{Tumor heterogeneity}{section.5.1}% 54
\BOOKMARK [2][-]{subsection.5.1.2}{Treatment resistance}{section.5.1}% 55
\BOOKMARK [1][-]{section.5.2}{From sketches to sequencing data evolution information}{chapter.5}% 56
\BOOKMARK [2][-]{subsection.5.2.1}{Tumor evolution and heterogeneity}{section.5.2}% 57
\BOOKMARK [1][-]{section.5.3}{Useful measures from NGS pipeline}{chapter.5}% 58
\BOOKMARK [2][-]{subsection.5.3.1}{Informative SNPs in cancer studies}{section.5.3}% 59
\BOOKMARK [2][-]{subsection.5.3.2}{Coverage and AF properties}{section.5.3}% 60
\BOOKMARK [2][-]{subsection.5.3.3}{Computing Beta}{section.5.3}% 61
\BOOKMARK [1][-]{section.5.4}{Global vs Local Estimates of admixture}{chapter.5}% 62
\BOOKMARK [1][-]{section.5.5}{A challenging case \(PR-2741*\)}{chapter.5}% 63
\BOOKMARK [0][-]{chapter.6}{Tumor evolution studies \(continued\)}{part.1}% 64
\BOOKMARK [1][-]{section.6.1}{Analysis of clonality}{chapter.6}% 65
\BOOKMARK [2][-]{subsection.6.1.1}{Recalls from previous chapter}{section.6.1}% 66
\BOOKMARK [2][-]{subsection.6.1.2}{Cluster analysis, an example}{section.6.1}% 67
\BOOKMARK [1][-]{section.6.2}{Evolution maps}{chapter.6}% 68
\BOOKMARK [2][-]{subsection.6.2.1}{A toy example}{section.6.2}% 69
\BOOKMARK [2][-]{subsection.6.2.2}{Working with real data}{section.6.2}% 70
\BOOKMARK [2][-]{subsection.6.2.3}{Pathway based evolution analysis}{section.6.2}% 71
\BOOKMARK [1][-]{section.6.3}{Ploidy and purity correction on 2\(TN\) data}{chapter.6}% 72
\BOOKMARK [2][-]{subsection.6.3.1}{Melanoma example}{section.6.3}% 73
\BOOKMARK [2][-]{subsection.6.3.2}{Melanoma example with 25 samples}{section.6.3}% 74
\BOOKMARK [2][-]{subsection.6.3.3}{TCGA example}{section.6.3}% 75
\BOOKMARK [2][-]{subsection.6.3.4}{Allele-specific analysis}{section.6.3}% 76
\BOOKMARK [2][-]{subsection.6.3.5}{A Case study CNA, CNB real data example}{section.6.3}% 77
\BOOKMARK [0][-]{chapter.7}{Tumor evolution studies via NGS data: SNVs-based methods}{part.1}% 78
\BOOKMARK [1][-]{section.7.1}{Rationale of somatic point mutation based assays}{chapter.7}% 79
\BOOKMARK [1][-]{section.7.2}{TPES \(Tumor Purity Estimation\)}{chapter.7}% 80
\BOOKMARK [1][-]{section.7.3}{How many SNVs are needed to assess tumor purity?}{chapter.7}% 81
\BOOKMARK [1][-]{section.7.4}{Comparison between purity callers}{chapter.7}% 82
\BOOKMARK [1][-]{section.7.5}{Pros and Cons of SNVs-based tumor purity assessment}{chapter.7}% 83
\BOOKMARK [0][-]{chapter.8}{Liquid biopsies in oncology}{part.1}% 84
\BOOKMARK [1][-]{section.8.1}{General considerations}{chapter.8}% 85
\BOOKMARK [1][-]{section.8.2}{Issues in the interpretation of cfDNA data}{chapter.8}% 86
\BOOKMARK [2][-]{subsection.8.2.1}{Normalization on tumor content}{section.8.2}% 87
\BOOKMARK [2][-]{subsection.8.2.2}{Quantity of input material}{section.8.2}% 88
\BOOKMARK [1][-]{section.8.3}{SNV detection in liquid biopsies}{chapter.8}% 89
\BOOKMARK [1][-]{section.8.4}{Requirements depend on the application}{chapter.8}% 90
\BOOKMARK [1][-]{section.8.5}{Whole genome vs targeted sequencing}{chapter.8}% 91
\BOOKMARK [1][-]{section.8.6}{Case studies}{chapter.8}% 92
\BOOKMARK [2][-]{subsection.8.6.1}{Case I}{section.8.6}% 93
\BOOKMARK [2][-]{subsection.8.6.2}{Case II}{section.8.6}% 94
\BOOKMARK [1][-]{section.8.7}{Take-home message}{chapter.8}% 95
\BOOKMARK [2][-]{subsection.8.7.1}{Challenges in the tracking of tumor evolution}{section.8.7}% 96
\BOOKMARK [0][-]{chapter.9}{Extracellular vesicles}{part.1}% 97
\BOOKMARK [1][-]{section.9.1}{Definition}{chapter.9}% 98
\BOOKMARK [1][-]{section.9.2}{Characterization}{chapter.9}% 99
\BOOKMARK [2][-]{subsection.9.2.1}{Size}{section.9.2}% 100
\BOOKMARK [2][-]{subsection.9.2.2}{Origin}{section.9.2}% 101
\BOOKMARK [2][-]{subsection.9.2.3}{Content}{section.9.2}% 102
\BOOKMARK [1][-]{section.9.3}{The importance of EVs}{chapter.9}% 103
\BOOKMARK [2][-]{subsection.9.3.1}{Role in cancer}{section.9.3}% 104
\BOOKMARK [1][-]{section.9.4}{How can we use them to study cancer? \(or any other disease\)}{chapter.9}% 105
\BOOKMARK [2][-]{subsection.9.4.1}{Tracking tumor signal in serial samples}{section.9.4}% 106
\BOOKMARK [2][-]{subsection.9.4.2}{Different EVs isolation methods}{section.9.4}% 107
\BOOKMARK [2][-]{subsection.9.4.3}{Challenges}{section.9.4}% 108
\BOOKMARK [2][-]{subsection.9.4.4}{Approaching deconvolution}{section.9.4}% 109
\BOOKMARK [1][-]{section.9.5}{Conclusions}{chapter.9}% 110
\BOOKMARK [0][-]{chapter.10}{Epigenetic profiling of cell-free DNA}{part.1}% 111
\BOOKMARK [1][-]{section.10.1}{Introduction}{chapter.10}% 112
\BOOKMARK [1][-]{section.10.2}{DNA methylation}{chapter.10}% 113
\BOOKMARK [1][-]{section.10.3}{How is DNA methylation measured?}{chapter.10}% 114
\BOOKMARK [1][-]{section.10.4}{Tissue-specific vs disease-specific DNA markers}{chapter.10}% 115
\BOOKMARK [1][-]{section.10.5}{DNA methylation based liquid biopsy}{chapter.10}% 116
\BOOKMARK [2][-]{subsection.10.5.1}{Workflow}{section.10.5}% 117
\BOOKMARK [2][-]{subsection.10.5.2}{CCGA study}{section.10.5}% 118
\BOOKMARK [2][-]{subsection.10.5.3}{Deconvolution approaches}{section.10.5}% 119
\BOOKMARK [1][-]{section.10.6}{Targeted panel approaches for tumor content estimation}{chapter.10}% 120
\BOOKMARK [-1][-]{part.2}{II Papers}{}% 121
\BOOKMARK [0][-]{chapter.11}{Role of non-coding sequence variants in cancer}{part.2}% 122
\BOOKMARK [1][-]{section.11.1}{Abstract}{chapter.11}% 123
\BOOKMARK [2][-]{subsection.11.1.1}{Introduction}{section.11.1}% 124
\BOOKMARK [1][-]{section.11.2}{Genomic sequence variants}{chapter.11}% 125
\BOOKMARK [1][-]{section.11.3}{Non-coding element annotation}{chapter.11}% 126
\BOOKMARK [2][-]{subsection.11.3.1}{Cis regulatory regions}{section.11.3}% 127
\BOOKMARK [2][-]{subsection.11.3.2}{Distal regulatory elements}{section.11.3}% 128
\BOOKMARK [2][-]{subsection.11.3.3}{RNA-seq}{section.11.3}% 129
\BOOKMARK [2][-]{subsection.11.3.4}{Transcribed pseudogenes}{section.11.3}% 130
\BOOKMARK [2][-]{subsection.11.3.5}{Evolutionary conservation}{section.11.3}% 131
\BOOKMARK [1][-]{section.11.4}{Roles for somatic variants in cancer}{chapter.11}% 132
\BOOKMARK [2][-]{subsection.11.4.1}{Gain of TF-binding sites}{section.11.4}% 133
\BOOKMARK [2][-]{subsection.11.4.2}{Fusion events due to genomic rearrangements}{section.11.4}% 134
\BOOKMARK [2][-]{subsection.11.4.3}{ncRNAs and their binding sites}{section.11.4}% 135
\BOOKMARK [2][-]{subsection.11.4.4}{Role of pseudogenes in modulating the expression of a parental gene}{section.11.4}% 136
\BOOKMARK [1][-]{section.11.5}{Roles for germline variants in cancer}{chapter.11}% 137
\BOOKMARK [2][-]{subsection.11.5.1}{Promoter mutations}{section.11.5}% 138
\BOOKMARK [2][-]{subsection.11.5.2}{SNPs in enhancers}{section.11.5}% 139
\BOOKMARK [2][-]{subsection.11.5.3}{Variants in introns}{section.11.5}% 140
\BOOKMARK [2][-]{subsection.11.5.4}{SNPs in ncRNA and their binding sites}{section.11.5}% 141
\BOOKMARK [2][-]{subsection.11.5.5}{Others}{section.11.5}% 142
\BOOKMARK [1][-]{section.11.6}{Interplay between germline and somatic variants}{chapter.11}% 143
\BOOKMARK [1][-]{section.11.7}{Computational methods for identifying variants}{chapter.11}% 144
\BOOKMARK [1][-]{section.11.8}{Experimental approaches for functional validation}{chapter.11}% 145
\BOOKMARK [0][-]{chapter.12}{Advances in understanding cancer genomics through second-generation sequencing}{part.2}% 146
\BOOKMARK [1][-]{section.12.1}{Abstract}{chapter.12}% 147
\BOOKMARK [2][-]{subsection.12.1.1}{Introduction}{section.12.1}% 148
\BOOKMARK [1][-]{section.12.2}{Cancer-specific consideration}{chapter.12}% 149
\BOOKMARK [2][-]{subsection.12.2.1}{Characteristics of cancer samples for genomic analysis}{section.12.2}% 150
\BOOKMARK [2][-]{subsection.12.2.2}{Structural variability of cancer genomes}{section.12.2}% 151
\BOOKMARK [1][-]{section.12.3}{Experimental approaches}{chapter.12}% 152
\BOOKMARK [2][-]{subsection.12.3.1}{Whole genome sequencing}{section.12.3}% 153
\BOOKMARK [2][-]{subsection.12.3.2}{Exome sequencing}{section.12.3}% 154
\BOOKMARK [2][-]{subsection.12.3.3}{Transcriptome sequencing}{section.12.3}% 155
\BOOKMARK [1][-]{section.12.4}{Detecting classes of genome alterations}{chapter.12}% 156
\BOOKMARK [2][-]{subsection.12.4.1}{Somatic nucleotide substitutions and small insertion and deletion mutations}{section.12.4}% 157
\BOOKMARK [2][-]{subsection.12.4.2}{Copy number}{section.12.4}% 158
\BOOKMARK [2][-]{subsection.12.4.3}{Chromosomal rearrangements}{section.12.4}% 159
\BOOKMARK [2][-]{subsection.12.4.4}{Microbe-discovery methods}{section.12.4}% 160
\BOOKMARK [1][-]{section.12.5}{Computational issues}{chapter.12}% 161
\BOOKMARK [2][-]{subsection.12.5.1}{Alignment and assembly}{section.12.5}% 162
\BOOKMARK [2][-]{subsection.12.5.2}{mutations detection}{section.12.5}% 163
\BOOKMARK [2][-]{subsection.12.5.3}{Validation of mutation and rearrangement calls}{section.12.5}% 164
\BOOKMARK [0][-]{chapter.13}{Integrative genomics viewer}{part.2}% 165
\BOOKMARK [1][-]{section.13.1}{Introduction}{chapter.13}% 166
\BOOKMARK [0][-]{chapter.14}{Tumour heterogeneity and resistance to cancer therapies}{part.2}% 167
\BOOKMARK [1][-]{section.14.1}{Abstract}{chapter.14}% 168
\BOOKMARK [2][-]{subsection.14.1.1}{Introduction}{section.14.1}% 169
\BOOKMARK [1][-]{section.14.2}{Causes of intratumoral heterogeneity}{chapter.14}% 170
\BOOKMARK [2][-]{subsection.14.2.1}{Genomic instability}{section.14.2}% 171
\BOOKMARK [2][-]{subsection.14.2.2}{The clonal evolution and selection hypothesis}{section.14.2}% 172
\BOOKMARK [1][-]{section.14.3}{The spectrum of tumour heterogeneity}{chapter.14}% 173
\BOOKMARK [2][-]{subsection.14.3.1}{Spatial heterogeneity}{section.14.3}% 174
\BOOKMARK [2][-]{subsection.14.3.2}{Temporal heterogeneity}{section.14.3}% 175
\BOOKMARK [1][-]{section.14.4}{Noninvasive monitoring of heterogeneity}{chapter.14}% 176
\BOOKMARK [2][-]{subsection.14.4.1}{Analysis of ctDNA}{section.14.4}% 177
\BOOKMARK [1][-]{section.14.5}{Overcoming heterogeneity}{chapter.14}% 178
\BOOKMARK [0][-]{chapter.15}{Unravelling the clonal hierarchy of somatic genomic aberrations}{part.2}% 179
\BOOKMARK [1][-]{section.15.1}{Introduction}{chapter.15}% 180
\BOOKMARK [2][-]{subsection.15.1.1}{Abstract}{section.15.1}% 181
\BOOKMARK [2][-]{subsection.15.1.2}{Background}{section.15.1}% 182
\BOOKMARK [1][-]{section.15.2}{Results}{chapter.15}% 183
\BOOKMARK [2][-]{subsection.15.2.1}{Clonality assessment of aberrations from sequencing reads}{section.15.2}% 184
\BOOKMARK [2][-]{subsection.15.2.2}{Inferring the order of mutations in a tumour sample}{section.15.2}% 185
\BOOKMARK [2][-]{subsection.15.2.3}{In silico and in situ experimental validation}{section.15.2}% 186
\BOOKMARK [2][-]{subsection.15.2.4}{Comparative analysis reveals different mechanisms of tumour deregulation}{section.15.2}% 187
\BOOKMARK [2][-]{subsection.15.2.5}{Clonal hierarchy of genomic aberrations}{section.15.2}% 188
\BOOKMARK [1][-]{section.15.3}{Materials and methods}{chapter.15}% 189
\BOOKMARK [2][-]{subsection.15.3.1}{CLONET pipeline}{section.15.3}% 190
\BOOKMARK [2][-]{subsection.15.3.2}{CLONET on exome and targeted sequencing data}{section.15.3}% 191
\BOOKMARK [2][-]{subsection.15.3.3}{Expected distribution of the allelic fraction of a genomic segment}{section.15.3}% 192
\BOOKMARK [2][-]{subsection.15.3.4}{Estimated proportion of neutral reads for a genomic segment}{section.15.3}% 193
\BOOKMARK [2][-]{subsection.15.3.5}{From neutral to non-aberrant reads}{section.15.3}% 194
\BOOKMARK [2][-]{subsection.15.3.6}{From aberrant reads to aberrant cells}{section.15.3}% 195
\BOOKMARK [2][-]{subsection.15.3.7}{Uncertainty assessment and its propagation to clonality estimates}{section.15.3}% 196
\BOOKMARK [2][-]{subsection.15.3.8}{Clonality of bi-allelic deletion}{section.15.3}% 197
\BOOKMARK [0][-]{chapter.16}{TPES: timor purity estimation from SNVs}{part.2}% 198
\BOOKMARK [1][-]{section.16.1}{Abstract}{chapter.16}% 199
\BOOKMARK [2][-]{subsection.16.1.1}{Introduction}{section.16.1}% 200
\BOOKMARK [1][-]{section.16.2}{Materials and methods}{chapter.16}% 201
\BOOKMARK [0][-]{chapter.17}{SNP panel identification assay \(SPIA\): a genetic-based assay for the identification of cell lines}{part.2}% 202
\BOOKMARK [1][-]{section.17.1}{Abstract}{chapter.17}% 203
\BOOKMARK [2][-]{subsection.17.1.1}{Introduction}{section.17.1}% 204
\BOOKMARK [1][-]{section.17.2}{Material and methods}{chapter.17}% 205
\BOOKMARK [2][-]{subsection.17.2.1}{Genotype distance}{section.17.2}% 206
\BOOKMARK [2][-]{subsection.17.2.2}{SNP panel selection procedure}{section.17.2}% 207
\BOOKMARK [2][-]{subsection.17.2.3}{SPIA probabilistic test on cell line genotype distance}{section.17.2}% 208
